$GILD Company News

New Post Public Reply Private Reply Replies (0) Message Board

Sep 15, 2014 at 10:00 AM

$GILD Company News

Gilead Sciences shares slide 2.6%
20 min ago9:39 a.m. Sept. 15, 2014
- Sue Chang

14 stocks loved by top-performing fund managers
8:29 a.m. Today8:29 a.m. Sept. 15, 2014
- Philip van Doorn

Two tech stocks with big potential
2:14 p.m. Sept. 11, 2014
- The Trading Deck

Why Apple exemplifies everything that’s wrong with Silicon Valley
12:51 p.m. Sept. 9, 2014
- Tim Mullaney

There’s good news for speculative growth traders
2:39 p.m. Sept. 2, 2014
- The Trading Deck

Trade what you see, not what you believe
2:48 p.m. Aug. 29, 2014
- The Trading Deck

Don’t read too much into this week’s action
2:01 p.m. Aug. 26, 2014
- The Trading Deck

Gilead Sciences shares rise 2.5% to pace S&P 500 gainers
9:34 a.m. Aug. 25, 2014
- Tomi Kilgore

Surviving "a complex time in the market"
4:57 a.m. Aug. 25, 2014
- MarketWatch

10 S&P 500 companies growing faster than their rivals
3:29 a.m. Aug. 20, 2014
- Philip van Doorn

10 stocks enjoying the biggest increases in earnings estimates
7:27 p.m. Aug. 12, 2014
- Philip van Doorn

Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices

4:17 p.m. Aug. 8, 2014
- blogs.marketwatch.com

Gilead says EU Committee to recommend approval of leukemia drug
7:32 a.m. July 25, 2014
- Ciara Linnane

Gilead says EU Committee to recommend approval of leukemia drug
7:26 a.m. July 25, 2014
- Ciara Linnane

S&P 500 ekes out another record close: stock market live blog recap

4:03 p.m. July 24, 2014
- blogs.marketwatch.com

Facebook surges to record; SodaStream bubbles higher
1:23 p.m. July 24, 2014
- Tom Bemis

Biotechs beat estimates, but the Street wants more

11:44 a.m. July 24, 2014
- blogs.marketwatch.com

Gilead trounces earnings views, but shares don't feel the after-hours love

5:39 p.m. July 23, 2014
- blogs.marketwatch.com

Updates, advisories and surprises
5:31 p.m. July 23, 2014
- MarketWatch

Facebook rallies in after hours as results top outlook
4:58 p.m. July 23, 2014
- Sue Chang

Trade-Ideas: Gilead (GILD) Is Today's Pre-Market Laggard Stock

8:52 a.m. Today8:52 a.m. Sept. 15, 2014
- TheStreet.com

Gilead to Allow Cheaper Hepatitis C Drug

7:19 a.m. Today7:19 a.m. Sept. 15, 2014
- The Wall Street Journal Interactive Edition

Gilead licenses Sovaldi to Indian firms

7:13 a.m. Today7:13 a.m. Sept. 15, 2014
- Seeking Alpha

Mylan In Pact With Gilead To Accelerate Access To Hepatitis C

5:31 a.m. Today5:31 a.m. Sept. 15, 2014
- benzinga.com

FDA tentatively approves Mylan's HIV combo

1:53 p.m. Sept. 13, 2014
- Seeking Alpha

Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog

5:25 p.m. Sept. 12, 2014
- Zacks.com

Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog

4:50 p.m. Sept. 12, 2014
- Zacks.com

Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog

4:30 p.m. Sept. 12, 2014
- Zacks.com

5 Top Stocks With Rising Earnings Estimates

7:02 a.m. Sept. 12, 2014
- Investors Business Daily

Medivation-Astellas' Xtandi's Label Expanded by FDA - Analyst Blog

6:35 p.m. Sept. 11, 2014
- Zacks.com

Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog

5:55 p.m. Sept. 11, 2014
- Zacks.com

Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog

5:45 p.m. Sept. 11, 2014
- Zacks.com

Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog

5:20 p.m. Sept. 11, 2014
- Zacks.com

Seattle Genetics-Genmab Expand Deal for Antibody Platform - Analyst Blog

5:15 p.m. Sept. 11, 2014
- Zacks.com

NPS Pharmaceuticals (NPSP) Shoots Up Ahead of FDA Panel - Analyst Blog

4:54 p.m. Sept. 11, 2014
- Zacks.com

Is This the Right Time to Buy Gilead Sciences (GILD) Stock? - Analyst Blog

4:45 p.m. Sept. 11, 2014
- Zacks.com

Medivation Eyes Blockbuster As Cancer Drug Gets An OK

4:41 p.m. Sept. 11, 2014
- Investors Business Daily

Orexigen's Obesity Drug Contrave Approved by the FDA - Analyst Blog

4:30 p.m. Sept. 11, 2014
- Zacks.com

Uncertainty Prevails For Vertex

3:48 p.m. Sept. 11, 2014
- Seeking Alpha

In A Quiet Week, Affimed Therapeutics IPO Could Garner Investor Interest

3:17 p.m. Sept. 11, 2014
- Seeking Alpha

Gilead Announces Generic Licensing Agreements to Increase Access to
Hepatitis C Treatments in Developing Countries
6:30 a.m. Today6:30 a.m. Sept. 15, 2014
- BusinessWire - BZX

Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries
6:30 a.m. Today6:30 a.m. Sept. 15, 2014
- PR Newswire - PRF

Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale
9:10 a.m. Sept. 12, 2014
- PR Newswire - PRF

Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver
9:31 a.m. Sept. 9, 2014
- PR Newswire - PRF

Global Hepatitis C Market 2014-2018
9:58 p.m. Sept. 8, 2014
- PR Newswire - PRF

Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher
9:20 a.m. Sept. 4, 2014
- PR Newswire - PRF

Gilead Sciences to Present at Two Upcoming Investor Conferences in
September
5:00 p.m. Sept. 3, 2014
- BusinessWire - BZX

Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay
9:05 a.m. Sept. 3, 2014
- PR Newswire - PRF

Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard
9:10 a.m. Aug. 27, 2014
- PR Newswire - PRF

Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver
9:31 a.m. Aug. 21, 2014
- PR Newswire - PRF

Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana
9:20 a.m. Aug. 19, 2014
- PR Newswire - PRF

Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health
9:10 a.m. Aug. 8, 2014
- PR Newswire - PRF

Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver
9:31 a.m. Aug. 4, 2014
- PR Newswire - PRF

Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis
9:20 a.m. July 31, 2014
- PR Newswire - PRF

Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
8:40 a.m. July 31, 2014
- PR Newswire - PRF

Theraclone Announces Exclusive Agreement with Gilead Sciences for
Broadly Neutralizing HIV Antibodies
8:00 a.m. July 30, 2014
- BusinessWire - BZX

European CHMP Adopts Positive Opinion for Gilead’s Zydelig®
(idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and
Follicular Lymphoma
7:24 a.m. July 25, 2014
- BusinessWire - BZX

Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic
10:03 a.m. July 24, 2014
- ACCESSWIRE

The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF)
12:30 a.m. July 24, 2014
- PR Newswire - PRF

Gilead Announces New Agreement with Medicines Patent Pool for Access
to Medicines in Developing World Countries
12:00 a.m. July 24, 2014
- BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...

xFusion Tackles Cooling and Power at OCP 2026

Bracing for an AI Revolution Ah, the world of AI — it's like the wild west out there, with data centers struggling to keep up as workloads skyrocket. Enter xFusion, a veteran in the computing infrastructure game, rolling out some seriously impressive tech at the 2026 Open Compute Project (OCP) Global Summit. The company's latest offering showcases how they're tackling...

JiMMYBAR! Unveils World's First Creatine Trail Mix

The New Face of Snacking: Creatine Trail Mix I'll tell you right off the bat, JiMMYBAR! seems to be cornering the snack world with an odd—but interesting—twist. They've just launched the world's first Creatine + Protein Trail Mix, blending muscle-building nutrients with the classic crunch of trail mix. Sounds quirky, and it’s exclusive to their site, JiMMYBARs.com....

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...

AI-Powered Travel Transformation in Norway Revealed

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

FCS Drives Key FDA Approvals in Cancer Treatment

Florida Cancer Specialists: Changing the Cancer Treatment Game Some organizations toot their horns, but every now and then, a group truly shakes up the playing field. Take Florida Cancer Specialists & Research Institute (FCS), for instance. Over years of relentless research, FCS has nailed its role in securing two significant FDA approvals aimed at expanding treatment...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

Cogent Communications' Q3 2026 Earnings Call Details

Cue the Countdown: Cogent’s Earnings Call Looms Another quarter rolls by, and with it comes Cogent Communications' chance to strut—or stumble—before the crowd. Their third-quarter earnings call on November 5, 2026, is like the opening bell for a stock that's zipped through more ups and downs than a tired bullfighter's routine. What the call reveals on that crisp...